Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Car Dealerships Shift Focus, Relying More on Parts and Service

Car dealerships face a significant evolution as they navigate declining gross profits, primarily influenced by the challenges stemming from recent years. With the automotive market still grappling with the fallout ofSupplychain disruptions and changing consumer demands, dealerships have shifted theirRevenuestrategies. As a result, a …

Vinay Lochav | 19 August 2026

Heidelberger Druckmaschinen (OTC: HBGRY) Q1 Revenue Climbs 9% to $2.66B, Surpassing Expectations

The company recorded a revenue increase of 9% year-over-year, reaching $2.66 billion, which is notable during a period marked byVolatilityin the broader machinery market. This performance is key for the company as it looks to stabilize its market position and regain investor trust after …

Vinay Lochav | 19 August 2026

INNIO (NASDAQ: INIO) Announces $300M Wisconsin Facility Expansion, Adding 500 Jobs

INNIO N.V. (NASDAQ: INIO), a key player in the industrial machinery sector with a marketCapitalizationof approximately $19.5 billion, is embarking on a $300 million facility expansion in Waukesha, Wisconsin. This majorInvestmentis projected to generate over 500 new jobs, significantly bolstering local employment and reflecting …

Vinay Lochav | 19 August 2026

Oxford Nanopore (OTC: ONTTF) Revenues Climb 12.3% to £116.7M Amid Challenges

Oxford Nanopore Technologies PLC (OTC: ONTTF), a company operating in the biotechnology sector with a marketCapitalizationof $1.61 billion, reported first-half revenue of £116.7 million, reflecting a 12.3% increase at constant currency. However, this figure fell short of analyst expectations as it faced challenges from …

Vinay Lochav | 19 August 2026

Teva's Ecopipam NDA Accepted by FDA, Targets Pediatric Tourette Treatment

Teva Pharmaceuticals announced a significant milestone with the FDA's acceptance of itsNew Drug Application (NDA)for ecopipam, targeting pediatric patients suffering from Tourette syndrome. This acceptance, supported by positive Phase 3 trial data, highlights the drug's effectiveness in reducing tic severity and fulfilling an urgent …

Vinay Lochav | 19 August 2026

Melanoma Vaccine Breakthrough Fuels Moderna 90% Share Surge

Moderna (NASDAQ: MRNA) shares catapulted 90% in trading today following positive late-stage clinical trial results for its experimental cancer vaccine developed inPartnershipwith Merck. The combination regimen, targeting melanoma, demonstrated a significant extension in the time patients lived without their cancer returning, offering a material …

Vinay Lochav | 19 August 2026

Bankruptcy Fears Ignite Calls for Enhanced Medicare Coverage

The discussion around expanding Medicare to include catastrophic coverage is intensifying, fueled by widespread concerns about the rising rate of personal bankruptcies linked to healthcare expenses. Advocates argue that the current Medicare framework insufficiently protects patients from the economic fallout of serious medical issues, …

Vinay Lochav | 19 August 2026

Biodexa's Serenta Trial Recruits Over 50% of Target Ahead of Timeline

Biodexa Pharmaceuticals PLC has made significant strides in its Phase 3 trial for treatments targeting Familial Adenomatous Polyposis (FAP), achieving recruitment of 87 out of a planned 168 subjects. This represents over 50% of the target enrollment, illustrating the company's strong progress in a …

Vinay Lochav | 19 August 2026

Cardinal Health (NYSE: CAH) Revenue Rises 14.2% to $254.25B, Driven by Precision Medicine

Cardinal Health, Inc. (NYSE: CAH), a leading medical distributor operating with a marketCapitalizationof $54.7 billion, reported impressive results, showcasing revenue of $254.25 billion for the recent fiscal quarter. The revenue reflects a strong year-over-year increase of 14.2%, signaling strongDemandfueled by the company's focus on …

Vinay Lochav | 19 August 2026

Eli Lilly and J&J Shares Surge on Positive Drug Data Amid Software Sell-Off

Eli Lilly and Johnson & Johnson are experiencing notable gains, propelled by positive results from their latest clinical studies that have caught the attention of investors. The emerging data suggests potential breakthroughs in their drug pipelines, reflecting advancements in healthcare innovation. This surge comes …

Vinay Lochav | 19 August 2026
Support

Hi! How can we help you today?

Loading…